Edelman R, Levine M M
Division of Geographic Medicine, University of Maryland, School of Medicine, Baltimore 21201.
Md Med J. 1991 Mar;40(3):199-203.
Considerable progress has been made in the past decade in developing vaccines against the most important bacterial and viral infections of the gastrointestinal tract. Members of the Division of Geographic Medicine in the Center for Vaccine Development have played a prominent role in the laboratory development and clinical testing of these vaccines. A new oral typhoid vaccine, Ty21a, has been licensed in the United States. A genetically engineered live oral cholera vaccine developed in the CVD is undergoing clinical trials in cholera-endemic areas. Multiple vaccine candidates against Shigella, enterotoxigenic E. coli, and rotavirus are in clinical trial in the United States or overseas. Rapid advances in molecular biology, together with new knowledge of mucosal and cellular immunity, will produce more vaccine candidates in the future. The CVD intends to be in the forefront of these developments.
在过去十年中，针对胃肠道最重要的细菌和病毒感染研发疫苗方面取得了相当大的进展。疫苗研发中心地理医学部的成员在这些疫苗的实验室研发和临床试验中发挥了突出作用。一种新的口服伤寒疫苗Ty21a已在美国获得许可。疫苗研发中心研发的一种基因工程口服霍乱活疫苗正在霍乱流行地区进行临床试验。多种针对志贺氏菌、产肠毒素大肠杆菌和轮状病毒的候选疫苗正在美国或海外进行临床试验。分子生物学的快速发展，以及对粘膜和细胞免疫的新知识，将在未来产生更多的候选疫苗。疫苗研发中心打算在这些发展中处于领先地位。
